Publicaciones en colaboración con investigadores/as de Hospital del Mar (59)

2023

  1. Distinct GSDMB protein isoforms and protease cleavage processes differentially control pyroptotic cell death and mitochondrial damage in cancer cells

    Cell Death and Differentiation, Vol. 30, Núm. 5, pp. 1366-1381

  2. Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis

    Clinical and Translational Oncology, Vol. 25, Núm. 4, pp. 941-958

  3. miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer

    Cancers, Vol. 15, Núm. 7

2022

  1. Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

    Science Advances, Vol. 8, Núm. 20

  2. mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer

    Molecular Cancer Research, Vol. 20, Núm. 7, pp. 1108-1121

2021

  1. Preclinical and clinical characterization of fibroblast-derived neuregulin-1 on trastuzumab and pertuzumab activity in HER2-positive breast cancer

    Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5096-5108

2020

  1. Autocrine CCL5 effect mediates trastuzumab resistance by ERK pathway activation in HER2-positive breast cancer

    Molecular Cancer Therapeutics, Vol. 19, Núm. 8, pp. 1696-1707

  2. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease

    Journal of Clinical Investigation, Vol. 130, Núm. 9, pp. 4871-4887

  3. MicroRNA-33b Suppresses Epithelial–Mesenchymal Transition Repressing the MYC–EZH2 Pathway in HER2+ Breast Carcinoma

    Frontiers in Oncology, Vol. 10

  4. Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)

    European Journal of Cancer Care, Vol. 29, Núm. 4

  5. The hippo pathway transducers yap1/tead induce acquired resistance to trastuzumab in her2-positive breast cancer

    Cancers, Vol. 12, Núm. 5

  6. Tumor-associated fibroblasts promote HER2-targeted therapy resistance through FGFR2 activation

    Clinical Cancer Research, Vol. 26, Núm. 6, pp. 1432-1448

2019

  1. NK cell infiltrates and HLA class I expression in primary HER2 þ breast cancer predict and uncouple pathological response and disease-free survival

    Clinical Cancer Research, Vol. 25, Núm. 5, pp. 1535-1545

  2. Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases

    Breast Cancer Research and Treatment, Vol. 178, Núm. 2, pp. 251-261

  3. Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion

    European Journal of Cancer, Vol. 120, pp. 54-64

  4. High numbers of circulating CD57+ NK cells associate with resistance to her2-specific therapeutic antibodies in HER2+ primary breast cancer

    Cancer Immunology Research, Vol. 7, Núm. 8, pp. 1280-1292

  5. The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER + breast cancer

    Nature Cell Biology, Vol. 20, Núm. 2, pp. 211-221

  2. Erratum to: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer (Nature Cell Biology, (2018), 20, 2, (211-221), 10.1038/s41556-017-0021-z)

    Nature Cell Biology

  3. Recent insights into the development of preclinical trastuzumab-resistant HER2+ breast cancer models

    Current Medicinal Chemistry, Vol. 25, Núm. 17, pp. 1976-1998